PATENT CLAIM ANALYSIS

Application Number: 16113611
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["544", "180000"]

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Claim (Index 1):
A compound represented by Formula I or a pharmaceutically acceptable salt, ester, or combination thereof: wherein R 1  is selected from: each of which is optionally further substituted when possible, wherein R 5  is selected from the group consisting of: 1) Hydrogen; 2) Optionally substituted \u2014C 1 -C 8  alkyl; 3) Optionally substituted \u2014C 2 -C 8  alkenyl; 4) Optionally substituted \u2014C 2 -C 8  alkynyl; 5) Optionally substituted \u2014C 3 -C 8  cycloalkyl; 6) Optionally substituted aryl; 7) Optionally substituted arylalkyl; 8) Optionally substituted 3- to 8-membered heterocycloalkyl; 9) Optionally substituted heteroaryl; and 10) Optionally substituted heteroarylalkyl; X 1 , X 2 , X 3  and X 4  are each independently selected from N and C(R 6 ); R 2  and R 6  are each independently selected from the group consisting of: 1) Hydrogen; 2) Halogen; 3) \u2014NO 2 ; 4) Cyano; 5) Optionally substituted \u2014C 1 -C 8  alkyl; 6) Optionally substituted \u2014C 1 -C 8  cycloalkyl; and 7) Optionally substituted 3- to 8-membered heterocycloalkyl; R 3  and R 4  are each independently selected from the group consisting of: 1) Hydrogen; 2) Halogen; 3) \u2014NO 2 ; 4) Cyano; 5) Optionally substituted \u2014C 1 -C 8  alkyl; 6) Optionally substituted \u2014C 2 -C 8  alkenyl; 7) Optionally substituted \u2014C 2 -C 8  alkynyl; 8) Optionally substituted \u2014C 3 -C 8  cycloalkyl; 9) Optionally substituted aryl; 10) Optionally substituted arylalkyl; 11) Optionally substituted 3- to 8-membered heterocycloalkyl; 12) Optionally substituted heteroaryl; 13) Optionally substituted heteroarylalkyl; 14) \u2014OR 7 ; 15) \u2014N(R 7 )(R 8 ) 16) \u2014S(O) 2 N(R 7 )(R 8 ); 17) \u2014N(R 7 ) C(O) R 8 ; and 18) \u2014N(R 7 ) S(O) 2 R 8 ; wherein R 7  and R 8  are independently selected from the group consisting of hydrogen, \u2014C 1 -C 15  alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, all of which are optionally substituted with 1-3 substituents selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, \u2014CN, lower alkoxy, \u2014CF 3 , aryl, and heteroaryl, or R 7  and R 8  are taken together with the nitrogen atom to which they are attached to form a heterocyclic.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 96.0
- Lexical Diversity: 1.84416
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979128', '15988806', '15988783', '15988763', '15597431']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8439634053525058
- 35 USC 102 Novelty (BERT): 0.529966670279301
- Combined Prediction Score: 0.8125637318451853
- Mean Citation Score: 346.565066
- Max Citation Score: 375.6885
- Similarity Product: 327.7925389521718

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test